Palifermin is a recombinant human keratinocyte growth factor (KGF) that plays a crucial role in stimulating the growth and repair of epithelial cells. Initially developed by Amgen, palifermin is used primarily to reduce the incidence and duration of severe oral mucositis in patients undergoing high-dose chemotherapy and radiation therapy, followed by a hematopoietic stem cell transplant.
